ICD-10-CM 2027 diagnosis code

D3ABenign neuroendocrine tumors

Not billable — use a more specific code

D3A is a header code, so it can't be reported by itself. Choose one of the 2 more specific codes beneath it.

Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS, effective October 1, 2026. Updated September 29, 2026. About our data

About D3A

D3A is the ICD-10-CM diagnosis code for benign neuroendocrine tumors. It belongs to block D3A (benign neuroendocrine tumors) and chapter 2 (neoplasms). It is a header code, so it can't be reported by itself; one of its 2 subcodes must be used instead.

To report this condition, pick the subcode that matches the documentation: D3A.0 (tumors) and D3A.8 (tumors).

The conditions in its Excludes2 note aren't part of D3A, but may be coded alongside it if the patient has both: benign pancreatic islet cell tumors (D13.7).

Use an additional code to identify any associated endocrine syndrome, such as: carcinoid syndrome (E34.00).

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Specific codes under D3A

Coding notes

Excludes2Not included here — may be reported together if both conditions exist

benign pancreatic islet cell tumors (D13.7)

Use additional codeAdd a secondary code to fully describe the condition

code to identify any associated endocrine syndrome, such as:
carcinoid syndrome (E34.00)

Code alsoTwo codes may be needed; sequencing depends on circumstances

any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)

Notes that apply from higher levels

Instructions written at a parent level also apply to D3A.

Broader instructions also apply from Chapter 2: Neoplasms.

Code history

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027

FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
No changes since FY2016.

Common questions about D3A

Is D3A billable?: No. D3A is a header code. Report one of its more specific subcodes instead.